In this slide show we highlight some of the top news from the past year on genetic testing for cancer, including gene signatures for identifying different sub-types of breast cancer, the influence of genetics on RCC outcomes, and the utility of liquid biopsies.
Lori Smith, BSN, MSN, CRNP
We are fully aware that not all ovarian and peritoneal cancers are alike.
No matter what side of the aisle you sit on, no matter who you voted for and putting all things political aside, I think most of us as healthcare providers want only the best for our patients.
A study out of Johns Hopkins Bloomberg School of Public Health published results of a study evaluating the United States mortality rate associated with cervical cancer and what they found is concerning, especially for older and black wome
We all know the devastating effects of ovarian cancer on women globally. With the amount of women being diagnosed with or dying from the disease each year, it is clear that more drugs need to be approved for its treatment.
Bevacizumab (Avastin), an intravenous drug manufactured by Genentech, has received US Food and Drug Administration (FDA) approval for the treatment of platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal
Ovarian cancer is widely understood to be a challenging cancer to treat, as remission and survival rates are lower than many other gynecologic malignancies.
Are healthcare providers taking cancer survivors’ sexual health seriously? Are women (and men) being asked about their sexual health during and/or following treatment? Apparently not.
The Centers for Disease Control and Prevention (CDC) has changed recommendations on the human papillomavirus (HPV) vaccine schedule in 11- and 12-year-old children from 3 doses to 2 doses in at least 6-month intervals.
In 2016, it is estimated that there will be 22,280 newly diagnosed cases of ovarian cancer in the United States. Astonishing as it may seem, the lifetime risk for a woman developing ovarian cancer is 1 in 75, with a risk of death related to the disease being 1 in 100 (excluding low malignant potential tumors).